PINNED
PINNED
Streamlining Biomanufacturing of Personalised Cancer Immunotherapies with Synthetic DNA
13 October 2025 | By
A Synthetic DNA Approach for Speed, Scale & Flexibility
List view / Grid view
Articles
How artificial intelligence is the future of pharma
5 December 2016 | By Professor Jackie Hunter, BenevolentBio
Artificial Intelligence and machine learning present the industry with a real opportunity to do R&D differently, writes BenevolentBio's Jackie Hunter...
Versatile applications of next-generation sequencing in pharmaceutics
Next-generation sequencing (NGS) technologies hold great promise for unravelling the mysteries of biological systems, with the advent of DNA sequencing methods having greatly accelerated biomedical research, gaining broad applicability in disease diagnosis and therapeutics in recent years...
HTS assays for the identification of small-molecule inhibitors of deubiquitinating enzymes
The covalent modification of proteins by the attachment of ubiquitin (ubiquitination) is best known for its function to label proteins for proteasomal degradation. However, ubiquitination also plays non-proteasomal roles during signal transduction, DNA repair and protein sorting...
How to be a research scientist: A conversation with Novo Nordisk’s Rahul Kapur
23 November 2016 | By Rahul Kapur, Head of Medical Affairs, Novo Nordisk UK and Ireland
We caught up with Novo Nordisk’s Rahul Kapur, to find out what it’s like to be at the forefront of diabetes research and what it takes to get there...
D is for Diabetes
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
D is for Diabetes - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research into Diabetes...
C is for CRISPR
16 November 2016 | By Niamh Louise Marriott, Digital Content Producer
C is for CRISPR - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research of CRISPR technology
B is for Biomarkers
15 November 2016 | By Niamh Louise Marriott, Digital Content Producer
B is for Biomarkers - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of biomarkers.
A is for Alzheimer’s disease
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A is for Alzheimer's - the first instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the fight against this deadly disease
Human endogenous retrovirus expression as targets for multiple sclerosis
9 November 2016 | By Dr Hervé Perron, co-founder and Chief Scientific Officer of GeNeuro
GeNeuro's co-founder and CSO Dr Hervé Perron discusses how a HERV protein could be a target for a novel approach in treating multiple sclerosis...
IVF babies: Easy as 1, 2…3?
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The ethics of three parent babies has been widely debated - should it be used to save children from deadly mitochondrial diseases or are scientists "playing God"? Here's everything you need to know to decide...
Predictions for the future: How nanoscience will improve our health and lives
27 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers at UCLA discuss the growing trend of nanoscience, making their scientific predictions for the future of this tech and its global impact...
Rural, poor and sick: The unseen cancer crisis in America
20 October 2016 | By Aaron Yao, PhD, University of Virginia School of Medicine
PhD student Aaron Yao highlights the shocking disparities between rural and urban eastern America and how the odds of cancer survival do not favour the impoverished...
Basel Life Science Week 2016: A “flurry of scientific intellect”
10 October 2016 | By J.T. Kaminski, Director of Technology Services EMEA at IDBS
Drug Target Review brought you all the latest research and development live from the conference. Now read IDBS' J.T. Kaminski's round up of the event...
Vigilin: Could this drug target prevent a heart attack?
27 September 2016 | By ETH Zürich
Scientists identified a protein in liver cells, known as vigilin, which regulates the release of fats from the liver into the bloodstream. Find out more...
Drug Target Review – Issue #3 2016
20 September 2016 | By Drug Target Review
In Issue #3 2016: Flow Cytometry, Enzymes, Imaging, GPCRs, Hit-To-Lead, CNS, Companion Diagnostics, and much more...
